New inhaled therapy for severe lung failure enters first human tests
NCT ID NCT07558538
First seen May 02, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This early-stage study tests a single inhaled dose of a lab-made protein (rhKGF-2) in 24 adults with moderate-to-severe ARDS who are on a breathing machine. The main goal is to see if the drug is safe and tolerable, while also checking for signs it might improve oxygen levels. Participants receive either the drug or standard care alone, and are followed for 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ShanghaiZhongshan
Shanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.